Immunoglobulin Levels in Multiple Myeloma Patients Receiving a BCMA-Directed Therapy
Tests immunoglobulin dosing levels in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Key facts
- Where
- Lévis and Québec, CanadaSee the 2 sites
- Phase
- Phase 4
Where in Canada
- Santé Québec Chaudière-AppalachesLévis, CanadaTaking people
- Centre Intégré de CancérologieQuébec, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CHU de Quebec-Universite Laval
- Trial code
- NCT07094048
- Record updated
- 22 July 2026
- Original description
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.Read full original descriptionShow less
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Inclusion: Multiple myeloma patient:; ≥ 18 years old; ≥ 1 prior lines of therapy; Receiving a BCMA-directed T-cell Engager therapy (starting on treatment); On previous Ig support or not.
Exclusion: Less than 18 years old; Pregancy or breastfeeding.